drugset / Trial / NCT06251492
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the efficacy of 2 cycles of combinatory adebrelimab and stereotactic radiotherapy, followed by monotherapy adebrelimab in patients with metastatic castration-resistant prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.
Timeline
- Start
- 2024-01-30
- Primary completion
- 2025-07-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 20 mg/kg | Intravenous |